CJC-1295 with DAC has early human studies showing that it changes growth-hormone signals. That is not the same as proving useful fat-loss, muscle, recovery or anti-ageing benefits. It is not an approved medicine for those uses.
Still uncertain: Meaningful fat-loss, muscle-gain, recovery or anti-ageing benefit, long-term safety or equivalence of marketplace formulations.
By confirming your subscription, you agree to receive occasional WhichPeps Evidence Updates. Kit processes the signup and email delivery for WhichPeps. Privacy. Unsubscribe anytime.
What does the evidence mean in simple terms? table
What is it?
Long-acting GHRH analogue peptide
Entity type
Peptide analogue / modified peptide
Research focus
Growth-hormone axis research
Human evidence
Small early human studies show sustained GH and IGF-I elevation after CJC-1295 with DAC, establishing endocrine target engagement but not body-composition, recovery or anti-ageing efficacy.
Regulatory status
Not FDA-approved; FDA lists CJC-1295 among substances with significant safety concerns in compounding.
Main limitations
Meaningful fat-loss, muscle-gain, recovery or anti-ageing benefit, long-term safety or equivalence of marketplace formulations.
Safety
Endocrine effects are expected; FDA has reported serious adverse events including increased heart rate and systemic vasodilatory reactions in available CJC-1295 data.
Evidence reviewed
2026-09-18
i
Small early human studies show sustained GH and IGF-I elevation after CJC-1295 with DAC, establishing endocrine target engagement but not body-composition, recovery or anti-ageing efficacy.
Outcome-level evidence
Evidence is not one score.
Each record below answers a narrower question about an outcome, population or context. Evidence status and the study finding are shown separately so strong evidence is not mistaken for a positive effect.
FDA states available clinical data are limited and has identified serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction.
Endocrine effects are expected; FDA has reported serious adverse events including increased heart rate and systemic vasodilatory reactions in available CJC-1295 data.
FDA reports limited clinical data and serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction; long-term safety and immunogenicity remain inadequately characterized.
Technical details
Mechanism / biologyGHRH analogue with drug-affinity-complex technology that prolongs exposure and stimulates GH/IGF-1 secretion.
Route / formulation boundaryCJC-1295 with DAC is not interchangeable with informal 'CJC without DAC' products.
Identity / data-quality noteUse the canonical compound identity and studied formulation when interpreting evidence.
Study / label regimen evidenceVerified study/label regimen evidence is available. Published human pharmacology regimen. Open descriptive regimen evidence →
WhichPeps does not rely on a single headline study when the evidence base is broader. Primary research, registries, regulators and supporting records are kept distinct.
2structured study records
3outcome records
4linked source records
How to read these counts: they show evidence coverage, not evidence strength. One large, well-designed study can be more informative than several weak or indirect records.
Show supporting and discovery sources
Study pages above contain the records used for public evidence summaries. The links below include supporting, regulatory and literature-discovery sources; a registry or search result is not treated as proof of benefit.
Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.
